Systemic analysis of thrombectomy enhancement in acute ischaemic stroke treatment
Original framing: “[Comment] Tirofiban and thrombectomy for acute ischaemic stroke” — The Lancet
The scientific evaluation of tirofiban and thrombectomy is rigorous, with randomized controlled trials providing evidence of efficacy. However, the evidence base is often limited to high-income settings and does not account for broader health system constraints.
The systemic analysis of stroke care reveals that while pharmacological and technical advancements like tirofiban and thrombectomy are valuable, they must be embedded within a broader public health framework.
This includes addressing social determinants of health, integrating cross-cultural and indigenous knowledge, and expanding access to care in underserved regions. Historical patterns of medicalization and marginalization must be disrupted through inclusive policy and community-led initiatives. By weaving together scientific evidence, cultural wisdom, and systemic equity, we can move toward a more holistic and effective approach to stroke prevention and treatment.